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Enzymes of cyclic 3',5'-nucleotide metabolism in human renal
cortex and renal adenocarcinoma. Since anomalies in the metabo-
lism of cyclic adenosine monophosphate (cAMP) and cyclic
guanosine monophosphate (cGMP) may be associated with neo-
plasias either as a cause or a consequence, we have investigated
enzymes of cAMP and cOMP metabolism from normal human
renal cortical tissue and from renal adenocarcinomatous tissue.
Specific activities of adenylate cyclase—basal or stimulated by
sodium fluoride or by 5'-guanylylimidodiphosphate—were similar
in subcellular fractions from the tissues of normal cortex and
adenocarcinoma. In contrast to that in cortex, adenylate cyclase in
adenocarcinoma was unresponsive to parathyroid hormone, cal-
citonin, and vasopressin, and stimulation by prostaglandins PGE1
and POE2 was decreased. Adenylate cyclase from renal adeno-
carcinoma composed of "clear cells" was also unresponsive to
glucagon (GLU) and l-isoproterenol (ISO). Adenylate cyclase
from adenocarcinoma composed of "dark cells," in contrast, had
higher responsiveness to GLU and ISO. In cortex, the highest
specific activity of guanylate cyclase was in particulate fractions,
whereas in adenocarcinoma, the specific activity of soluble guany-
late cyclase was higher than that of particulate fractions and also
than in cytosol from normal cortex. Guanylate cyclase in all frac-
tions was stimulated by 1 mi azide in both cortex and adenocarci-
noma. The specific activities of cAMP phosphodiesterase from
subcellular fractions of clear-cell adenocarcinoma did not differ
from that of cortex, whereas the specific activities of this enzyme
from dark-cell tumors was markedly higher. Cyclic OMP
phosphodiesterase specific activity from cytosol of clear-cell
adenocarcinoma was lower than that in the cortex, but the enzyme
activity in dark-cell adenocarcinoma cytosol was higher than that
in cortex. These results suggest that the accumulation of lipids and
glycogen in the clear-cell adenocarcinoma may be due to an unre-
sponsiveness of tumor-cell-adenylate cyclase to GLU and fJ-cate-
cholamines. Observations also suggest that changes in enzymes of
cyclic 3',5'-nucleotide metabolism may favor higher accumulation
of cGMP and lower accumulation of cAMP in renal adenocarci-
noma.
Enzymes du métabolisme du 3',S'-nucléotide cyclique dans le cor-
tex renal et l'adénocarcinome renal humain. Du fait que des anoma-
lies du métabolisme du cAMP et du cUMP peuvent être associCes
avec une néoplasie soit comme une cause soit comme une con-
sequence, nous avons Ctudié les enzymes do métabolisme du cAMP
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et du cOMP du cortex renal et de l'adénocarcinome renal humains.
Les activités spécifiques de I'adenylate cyclase, basales ou stimulées
par NaF ou par GPPNHP sont semblables dans les fractions
subcellulaires du cortex normal et de l'adénocarcinome. A Ia diffé-
rence de celle du cortex, l'adénylate cyclase de I'adénocarcinome ne
répond pas a l'hormone parathyroldienne (PTH), a Ia calcitonine,
et a Ia vasopressine; Ia stimulation par les prostaglandines POE1
et POE2 est moindre. L'adenylate cyclase d'adénocarcinome renal
compose de cellules claires ne répond pas non plus au glucagon
(GLU) et au l-isoprotCrénol (ISO). L'adCnylate cyclase de
l'adénocarcinome compose de cellules sombres, au contraire, a une
réponse supérieure a GLU et ISO. Dans le cortex, l'activité spéci-
fique Ia plus élevée de Ia guanylate cyclase est située dans les
fractions particulaires alors que dans I'adénocarcinome l'activité
specifique de Ia guanylate cyclase soluble est plus elevée que celle
des fractions particulaires et que celle du cytosol du cortex normal.
La guanylate cyclase de toutes ces fractions est stimulCe par I'azide
1 ms aussi bien dans Ic cortex que dans l'adCnocarcinome. Les
activités specifiques de Ia cAMP phosphodiestérase des fractions
subcellulaires d'adénocarcinome a cellules claires ne sont pas dif-
férentes de celles du cortex, alors qu'elles sont supérieures dans Ic
cellules sombres tumorales. L'activitC spécifique de Ia cOMP
phosphodiestCrase est inférieure dans Ic cytosol d'adénocarcinome
a cellules claires, par rapport a celle du cortex, mais supérieure
dans I'adénocarcinome a cellules sombres. Les rCsultats suggèrent
que l'accumulation de lipides et de glycogène dans les adénocarci-
nomes a cellules claires peut être due a l'absence de réponse de
l'adénylate cyclase des cellules tumorales a GLU et aux beta-
catécholamines. Ces observations suggCrent aussi que les modifica-
tions des enzymes du mCtabolisme du 3',5'-nucléotide cyclique
peuvent favoriser une accumulation importante de cGMP et faible
de cAMP dans l'adénocarcinome renal.
Alterations of enzymes that determine the metabo-
lism of cyclic 3' ,5 '-adenosine monophosphate
(cAMP) and cyclic 3',5'-guanosine monophosphate
(cGMP) have been frequently found in cells and tis-
sues that are in the state of accelerated growth [1—3],
including neoplastically transformed cells. To date,
most studies have been done on normal and trans-
formed cells grown in tissue cultures or on tumors
induced experimentally in animals [1—3], but very
little direct information is available about the proper-
ties of enzymes of cyclic nucleotide metabolism in the
solid tumors occurring spontaneously in man [4—6].
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With respect to accelerated renal cell growth, some
enzymes of cAMP and cGMP metabolism were ex-
amined in rat kidney during hypertrophy or hyper-
plasia [7, 8] and in transplantable experimental renal
tumors [9], but no information is available on renal
tumors occurring spontaneously in man.
Renal (cortical) adenocarcinoma (RAC), the most
frequent epithelial renal tumor in man [10], is a
uniquely suitable system for studying directly in the
human renal tissue the changes in enzymes of cyclic
nucleotide metabolism due to neoplastic growth.
Light microscopic, electron microscopic [10—131, and
immunocytochemical [14] findings indicate that cells
of RAC are transformed cells, derived from proximal
convoluted tubules of renal cortex [10]. Cells of renal
cortical tissue [15], namely tubules [16, 17], are con-
trolled by many hormones and other humoral agents
acting to stimulate cAMP formation [15].
Two characteristic cell types differing in metabolic
properties [11, 18] are encountered in RAC [10—12].
The most frequent, the so-called "clear cell-type"
RAC, is composed of a cell population rich in intra-
cytoplasmic glycogen and lipids [10, 11, 18]. The
other type, which is seen much less frequently [10], is
composed solely of so-called "dark" or granular cells
[10, 11, 18]. In contrast to clear cells, dark cells
contain little or no lipids orglycogen [10, 11, 18], and
their dark or granular appearance is due to the high
density of intracellular organelles, such as mito-
chondria, Golgi apparatus, and endoplasmic retic-
ulum [10, 11]. Both cell types, however, contain
brush-border antigen [14], and both are considered to
originate from cells of the proximal tubule [10, 14,
18].
In order to determine possible alterations in en-
zymes of cyclic 3',5'-nucleotide metabolism and its
hormonal control in neoplastically transformed renal
tubular cells from human renal cortex, as well as to
examine the possible relationship of such changes to
biological properties of the tumor, we studied the
activities of adenylate and guanylate cyclases and
cyclic 3 ',S'-nucleotide phosphodiesterases in cell-free
preparations obtained from human RAC tissue and
compared them with the activities of enzymes from
untransformed renal cortical tissue of the host kid-
ney.
Methods
Tissues from kidneys of patients who underwent
nephrectomy because of renal masses were analyzed;
only tissues from kidneys of patients with histologi-
cally proven RAC and without concomitant renal or
nonrenal diseases were included. After surgical re-
moval, the renal tissue was chilled immediately in ice-
cold 0.9% sodium chloride. Subsequent preparatory
steps were also performed at 0 to 2°C [19]. Specimens
of macroscopically intact tissue were removed from
that region of the renal cortex most distant from the
tumor mass and from those areas of tumor macro-
scopically homogenous and without apparent necro-
sis or hemorrhagia. Frozen sections from an aliquot
of tissue, from which the enzyme preparations were
made, were examined by light microscopy to evaluate
identity of tissue, cell type, and homogeneity of cell
population in tumor specimens.
The enzyme extracts were prepared from intact
cortical tissue and simultaneously from tumorous tis-
sue of the same kidney by the following procedure.
The tissue was minced with scissors, rinsed in homog-
enizing medium (0.25 M sucrose, 5 mM Tris-hydro-
chloric acid, 3 m magnesium chloride, and 1 mrvi
ethylenediaminetetraacetic acid (EDTA) at pH 7.4),
and then homogenized in a glass-Teflon homogenizer
(tissue-to-medium ratio, about 1: 5 wt/vol). The
homogenate was centrifuged 600 X g for ten minutes,
and the resulting pellet was washed twice in homog-
enization medium without sucrose; the resulting
washed pellet—the crude nuclear fraction—to be re-
ferred to further as the 600 X g pellet, was suspended
in washing buffer and divided into small aliquots. The
supernate from the first centrifugation done at 600 X
g per ten minutes was centrifuged further at 10,000 X
g for 20 mm. The pellet was washed in homog-
enization medium, resuspended, and divided into
small aliquots. This preparation, corresponding to
the crude mitochondrial fraction, is referred to as the
l0 X g pellet. The supernate from the first centrifu-
gation done at 10,000 X g per 20 mm was ultracen-
trifuged at 100,000 X g for 60 mm. The medium-
washed pellet, corresponding to the crude micro-
somal fraction, is referred to as the l0 X g pellet.
The 100,000 X g for 60-mm supernate, containing
the fraction of cytoplasmic soluble proteins, is re-
ferred to as cytosol. To characterize further these
fractions, cytochrome c oxidase and lactate dehydro-
genase (LDH) activities as "marker enzymes" [20]
were determined in all fractions from three normal
cortices and from three tumors. The highest activity
of LDH—the cytoplasmic marker [20]—was found
in cytosol, and that of cytochrome c oxidase—the
mitochondrial marker [201—was found in the l0
X g pellet, both in normal cortex and in tumors.
After fractionation was completed, several aliquots
of the suspended pellets or cytosol were quickly fro-
zen in solid carbon dioxide and stored in a deep-
freeze chest at —70°C until assayed for enzyme activi-
ties. Storage up to 24 months had no effect on the
activity of enzymes or their responsiveness to hor-
174 Kim et a!
mones. Enzyme activities were assayed later only in
preparations from kidney specimens in which histo-
logic evaluation showed that cortical tissue was with-
out pathologic changes and that tumorous tissue was
composed of either clear-cell or dark-cell types of
RAC. When histologic examination showed tumors
of another nature or showed necrotic tissue or when
specimens contained mixture of tumorous and intact
cortical tissue, these preparations were discarded.
Only samples from kidneys of 20 patients fulfilled
these criteria. The average age of these patients (11
males and 9 females) was about 59 yr. From this
group, only three patients had homogeneous dark-
cell RAC, and 17 had homogeneous clear-cell RAC.
A deny/ate cyclase. Adenylate cyclase activity was
determined, using similar methods as in our previous
studies [19, 20]. The enzyme preparation (50 to 80tg
of protein/tube) was incubated for 15 mm at 37°C in
SOpl of incubation mixture having the following com-
position: 0.1 mri adenosine triphosphate labeled with
radioactive phosphorus ([a-32P]-ATP) (ICN Corp.,
Irvine, CA) (1 to 2 X 108 cpm), 4 mrvt magnesium
chloride, 0.1% bovine serum albumin (wt/vol), 0.1
mM EDTA, 0.5 mr'i cAMP, 25 mrvi creatine phos-
phate, 0.1 mg/ml of creatine kinase (Calbiochem,
San Diego, CA), and 40 mri Tris-hydrochioric acid
(pH 7.5). The incubation was stopped and analyzed
by using the method of Bar [21], as described pre-
viously [19]. In preliminary experiments, it was deter-
mined that cAMP formation is linear with time up to
20 mm and with protein up to l00g/tube for enzyme
preparations of normal cortex and tumor, with or
without the addition of hormones.
Guanylate cyclase. Guanylate cyclase was assayed
by the method described by Kimura and Murad [22],
which has been used previously in studies of guany-
late cyclase in kidneys of experimental animals [8, 9].
(Radioimmunoassay kits for determination of cGMP
were purchased from Swartz-Mann Laboratories.)
The incubation time was ten minutes at 37°C, and the
volume composition of the incubation mixture, as
well as other assay procedural details, was identical
to that described by Criss, Murad, and Kimura [9].
The enzyme was added in 20zl to the final volume of
the incubation mixture, lOOtl. Preliminary experi-
ments established that cGMP generation was linear
with time up to 20 mm and with protein up to 50tg of
protein per tube, for both particulate and soluble
preparations.
The activities of adenylate and guanylate cyclase
were expressed in pmoles of cGMP formed/rn in/mg
of protein.
cAMP and cGMP phosphodiesterase. Cyclic AMP
and cGMP phosphodiesterase activities were assayed
using incubation conditions identical to those de-
scribed in our previous study [20], except that at the
end of the second incubation, nucleosides were sepa-
rated from nucleotides by using the method described
by Wells et al [23]. Incubation time was five minutes
at 37° C; the concentration of substrates [3H]-cAMP
or [3H]-cGMP (New England Nuclear, Boston, MA)
was 10-6M. Enzyme activities were linear with time up
to 15 mm, and protein, up to 25kg/tube in tumor and
cortex tissue preparations. Use of the separation of
nucleotides from nucleosides on QAE Sephadex col-
umns [23] avoided the systematic underestimations
[24] of specific enzyme activities, which otherwise
occurred when AG-I (200 to 400 mesh) resin (Bio-
Rad Laboratories) was used as an ionic exchanger.
The protein kinase activity in the cytosol was as-
sayed in an incubation mixture having a total volume
of 200pi and containing the following ingredients in
final concentration: 10 m magnesium chloride, 2mM
theophylline, 0.3 mrvi ethylenebis-(oxyethylenenitrilo-)-
tetraacetic acid (EGTA), 10 m sodium fluoride, 2.5
X l0-6M [y32PJ-ATP (ICN Corp., Irvine, CA) (2
to 3 million cpm/tube), 100zg of mixed calf thymus
histones (type LI-A, Sigma Co., St. Louis, MO), and
50 m sodium fl-glycerophosphate (PH, 6.5). The
enzyme extract, containing 8 to l5g of protein per
tube, was incubated for five minutes at 30° C. The
inorganic phosphorus (P1) incorporated into protein
was determined by the method described elsewhere
[25]. In this extract, the protein kinase activity is
linear with enzyme protein, at least up to 25kg of
protein per tube, and was directly proportional to
time for at least eight minutes. The specific protein
kinase activity is expressed in pmoles of radioactive
phosphorus (32P) incorporated into protein per min-
ute per milligram of protein of enzyme extract. The
maximal stimulation by cAMP was at concentrations
between l0 and lO-5M. Lactate dehydrogenase
(LDH) and cytochrome c oxidase were assayed by
the same methods used in our previous study [20].
Protein in enzyme extracts was solubilized in 1% so-
dium lauryl sulfate [19, 20] and determined by the
method of Lowry et al [26].
The above described enzyme assays and protein
determinations were run in triplicate. Because of
known variability in the absolute specific activities of
enzymes from one assay to another, namely of the
adenylate cyclase [27, 28], enzymes from normal cor-
tex tissue and from tumorous tissue dissected from
the same kidney were assayed at the same time, using
the same batch of biochemicals, radiochemicals, or
hormones in order to minimize the variability in val-
ues for specific activity of enzymes and to allow direct
comparison of normal and tumor tissues. Student's t
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test, either for group or paired comparisons, was used
for statistical evaluation of the results. Values for P >
0.05 were considered not significant.
Results
The specific activities of enzymes in several basic
subcellular fractions, prepared as described in the
preceding Methods section, were studied first. Be-
cause of the limited quantity of tissue in some
specimens, it was not always possible to analyze all
fractions from each kidney.
Total tissue protein per wet weight did not differ
between normal cortex and RAC; likewise, the distri-
bution of total protein content among subcellular
fractions was not significantly different between RAC
and normal cortical tissue (see Table I).
Results of adenylate cyclase activity measurements
in subcellular fractions are shown in Table 2. In
normal cortical tissue, the highest specific activity of
the adenylate cyclase activity was in particulate frac-
tions, and in the presence of sodium fluoride or
5'-guanylylimidodiphosphate (Gpp[NHJp) (Swartz-
Mann Laboratories, Orangeburg, NY), the highest
specific activity was in the 600 X g pellet. In normal
cortex, the highest stimulation by parathyroid hor-
mone (PTH) (synthetic 1,34-N-terminal tetratria-
contapeptide bovine PTH, activity 3,800 lU/mg,
Beckman Instuments, Bioproducts, Palo Alto, CA)
was in the 600 X g pellet and was significantly (P <
0.02) less in other fractions.
Specific activities of adenylate cyclase in sub-
cellular fractions from RAC were, in general, similar
to those in normal cortex, with several exceptions: In
clear-cell RAC in the l0 X g pellet fraction, the in-
crease in activity after addition of Gpp(NH)p was
higher than in cortex; and in dark-cell RAC, higher
stimulation with sodium fluoride was noted in the l0
X g pellet (Table 2). In some series of experiments,
the basal specific activity of adenylate cyclase in the
600 X g pellet of RAC appear lower than in normal
cortex (see Tables 5, 6, 8), but this apparent differ-
ence was not consistent and statistically significant.
Cytosol from either cortex or RAC contained very
little of adenylate cyclase activity, namely when
assayed in the presence of sodium fluoride. The
major difference in properties of adenylate cyclase
between RAC and cortex was the complete lack of
stimulation of adenylate cyclase from RAC by PTH
(Table 2).
Cyclic AMP phosphodiesterase (Table 3) had the
highest specific activity in cytosol both in tumors and
in normal cortex. The specific activity of this enzyme
in any of the tested fractions was not significantly
different between cortex and clear-cell RAC; the spe-
cific activity of cAMP phosphodiesterase in the cyto-
sol of dark-cell RAC, however, was markedly higher
than that in either the cortex or the clear-cell RAC
(Table 3). Cyclic AMP phosphodiesterase in other
fractions of dark-cell RAC also appeared to be higher
than that in cortex or in clear-cell RAC.
Guanylate cyclase activity was detected in all frac-
tions of normal cortex homogenate and was signifi-
cantly stimulated by I m sodium azide in all frac-
tions (Table 4). Highest specific activity was found in
the 600 X g pellet, and the lowest was found in the
cytosol. In clear-cell RAC, guanylate cyclase was
likewise present and significantly stimulated by so-
dium azide in all fractions, but, in contrast to nor-
mal cortex, the highest specific activity was in cytosol.
Specific guanylate cyclase activity in the cytosol of
RAC was also significantly higher than that in the
cytosol from normal cortex (Table 4). Conversely,
specific activities in 600 X g and l0 X g pellets were
significantly lower in RAC than the activity in nor-
mal cortex. Guartylate cyclase activity in the cytosol
of three dark-cell RAC specimens was also higher
than that in normal kidney. (Activity in particulate
fractions was assayed only in one preparation of
dark-cell RAC [Table 4], but was also lower than that
in cytosol.)
The highest specific activity of cGMP phospho-
diesterase as well as that of cAMP phosphodiesterase
(Table 3) was in the cytosol; much lower specific
activities were found in the particulate fractions. In
clear-cell RAC specimens, the specific activities of
cGMP phosphodiesterase were significantly lower
than the activity in the cytosol and that in the l0 X
g pellet of normal cortex but not in other fractions
Table I. Protein content and distribution in normal cortical and in renal adenocarcinoniatous tissue (RAC) of the clear-cell types
Distribution of protein among
Tissue protein content
mg/g of wet weight
subcellular fractions, % of total protein
600 x g pellet l0 x g pellet l0 X g pellet Cytosol
Cortex 89.0± 13.1 42.2 10.1 3.4±0.4 44.0± 1.7
RAC 81.2 23.6 39.1 2.3 11.0 4.0 2.5 0.4 49.2 + 2.8
Values denote the mean ss; N = 4.
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Table 2. Specific activity of adenylate cyclase in subcel!ular fractions of normal cortex and renal adenocarcinoma tissue (RAC)a
Tissue and condtion
Specific adenylate cyclase activityb, pmoles/min/mg of protein
600 X g pellet l0 X g pellet 10' X g pellet Cytosol
Cortex
Basal
With 5tg/ml of PTH
With I02M sodium fluoride
With 104M Gpp(NH)p
7.3 1.1 (8)
69.2 + 6.2 (8)
93.2 7.2 (8)
52.1 + 9.7 (7)
6.6 + 1.2 (8)
40.2 8.6 (8)
68.8 16.1 (8)
29.1 + 7.06 (6)
3.2 + 0.6 (8)
4.9 0.9 (8)
39.1 + 5.9 (8)
15.3 2.9 (6)
0.5 0.1 (8)
0.8 + 0.2 (8)
3.2 + 0.7(8)
1.3 0.4(6)
Clear-cell RAC
Basal
With 5g/mI of PTI-1
With 102M sodium fluoride
With l04M Gpp(NH)p
11.5 + 2.4 (5)
12.2 3.1 (5)
90.2 22.6 (5)
74.8 + 21.8(5)
12.9 + 3.9 (5)
16.0 + 3.7 (5)
60.7 + 19.7 .(5)
66.3 + 15.2c (5)
3.4 1.1 (5)
3.6 + 1.1 (5)
27.3 7.2 (5)
12.8 3.6 (5)
0.6 + 0.2(5)
0.9 + 0.4 (5)
2.7 + 1.0(5)
0.8 0.4 (5)
Dark-cell RAC
Basal
With 5kg/mI of PTH
With l0-'M sodium fluoride
10.0 3.6 (3)
13.4 + 6.3 (3)
99.5 35.6 (3)
13.5 1.7 (3)
17.3 3.0 (3)
74.8 + 4.6 (3)
4.7 + 1.7 (3)
5.6 + 3.0 (3)
104.7 24.0" (3)
1.7 + 0.8 (3)
1.9 1.0(3)
11.3 + 5.0 (3)
Values are the mean SEM. Abbreviations used are I'TH, parathyroid hormone; Gpp(NH)p, 5'-guanylylimidodiphosphate.
bNumber of observations are in parentheses.
'Significantly higher than value for cortex under same conditions (P < 0.05).
"Significantly higher than clear-cell RAC and from cortex under same conditions (P < 0.01); except for activities measured in presence of
PTH, activities of the adenylate cyclase were not different between RAC and normal cortex, when evaluated by paired t test.
(Table 3). Cytosolic cGMP phosphodiesterase activ-
ity from dark-cell RAC was higher than the activity
of this enzyme in the cytosol of normal cortex or in
the clear-cell RAC tissue specimens (Table 3).
The regulatory effects of hormones and other hu-
moral agents on adenylate cyclase in normal cortex
and RAC were examined using the 600 X g pellet as
a source of enzyme, since this fraction was highest in
specific activity and had the highest responsiveness to
PTH as a prototype of hormonal agent acting on
cortical adenylate cyclase (Table 2). Stimulation by
PTH was dose-dependent; the dose for maximal
stimulation determined in preliminary experiments
was 0.l6g/ml + 0.07 (N = 5). Maximal stimulation
reached a plateau at concentrations > ljg/ml, and
the increase was greater than 700% over basal activity
(Tables 2 and 5). Adenylate cyclase from normal
renal human cortex was also stimulated significantly
by glucagon (GLU) (porcine crystalline glucagon, lot
M. GLF-599A, Eli Lilly & Co., Indianapolis, IN), 1-
isoproterenol (ISO) (Sigma Co., St Louis, MO), syn-
thetic [8-arginine}-vasopressin (AVP) (Schwartz-
Mann Laboratories), or calcitonin (CT) (purified
porcine CT, activity 116 MRC U/mg, lot no. K600-
072F-2, Armour Pharmaceutical Co., Kankakee, IL)
(Table 5), but maximal stimulation by these hor-
mones was much less than that with PTH—in gen-
eral, less than a 100% increase over the basal activity
Table 3. Specific activities of cyclic nucleotide diesterases and of lactic dehydrogenase (LDH)
cAMP phosphodiesterase
pmoles/min/mg of protein
cGMP phosphodiesterase
pmoles/min/mg of protein
LDH
unoles of DPHN/min/mg ofprotein
Fraction
Adenocarcinoma Adenocarcinoma
Cortex
Adenocarcinonia
Cortex Clear cells Dark cells Cortex Clear cell Dark cell Clear cell Dark cell
600 X g pellet
l0 >< g pellet
10' X g pellet
Cytosol
22.3 + 3.4 28.4 14.6 33.7 13.6
(N=7) (N=7) (N=3)
16.7 4.7 20.6 11.8 29.8 + 15.8
(N=7) (N=6) (N=3)
22.5 4.0 25.3 7.5 76.5 + 37.7
(N=7) (N=7) (N=3)
87.7 + 7.8 82.1 + 13.7 226.4 + 5l.2
(N = 13) (N= 10) (N= 3)
8.4 1.6 7.6 3.6 —
(N=7) (N=7)
6.5 + 1.6 7,0 2.9 —(N=7) (N6)
12.7 + 1.1 7.75 1.4' —
(N='7) (N=7)
57.3 + 4.33 35.3 5.7' 112.3 + 31.8"
(N= 13) (N= 10) (N = 3)
—
—
—
2.6 + 0.1
(N= 11)
— —
— —
— —
5.1 0.9" 2.9 0,9
(N = 8) (N = 3)
aValues represent the means s; number of observations are in parentheses.
5Significantly higher than values in cortex or in clear-cell RAC (P < 0.005).
csignificantly lower than value in cortex (P < 0.02).
Significantly higher than value in cortex (P < 0.005).
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Table 4. Specific activities of guanylate cyclase in subcellualr fractionsa
Tissue and condition
Specific activities of guanylate cyclase, pmoles/min/mg of protein
600 X g pellet 10" X g pellet 10' X g pellet Cytosol
Cortex
Basal 75.8 12.3 (6) 58.4 15.1 (6) 42.9 8.4 (6) 25.2 2.9 (9)
With 1 mi sodium azide 107.2 13 (6) 88.2 14.3 (6) 91.3 l5.9(6) 68.9 11.8 (9)%b +48+ 14 +65±23 +149+44 +171 +26
Clear-cell RAC
Basal 33.8 6.4c (6) 25.4 5.0' (6) 45.4 3.5 (6) 69.6 l82"(6)
With 1 mrvi sodium azide 75.2 19.2 (6) 78.0 8.6 (6) 128.7 13.2(6) 108.6 23.5 (6)
%b +126±40 +268±77 +268±77 77 +67+20
Dark-cell RAC
Basal 2.2 (1) 10.2 (1) 15.82 (I) 41.4+ 11.9" (3)
With I mr,i sodium azide 24.6 (1) 26.7 (1) 92.09 (1) 99.2 + 39.6 (3)% — — — +136+52
'Values represent the mean SEM; number of observations are in parentheses.
bpercentage increase (after addition of sodium azide) was significant in all fractions (P < 0.05 or better; paired I test).
eSingificantly lower than activity of corresponding fractions from cortex (P < 0.05 or better; paired : test).
dsignificantly higher than activity of cytosol from normal cortex (P < 0.05; paired t test).
(Table 5). Renal cortical adenylate cyclase was also
stimulated by prostaglandin E1 (POE1) and prosta-
glandin E2 (PGE2) (Upjohn Co., Kalamazoo, MI)
(Table 6), but not by their primary precursor, arachi-
donic acid (Sigma Co.). The prostaglandins appear to
act on the adenylate cyclase which is different from
that stimulated by PTH, since effects of POE2 and
PTH on human renal cortical adenylate cyclase were
additive (Table 6). In fractions other than the 600 X g
pellet of normal cortex from all previously men-
Table 5. Hormonal responsiveness of adenylate cyclase (600 g pellet) from normal human renal cortex and renal adenocarcinoma (RAC)'
Cortexb Adenocarcinomab
Case Sex and Type of Basal
no. age,yr tumorc activity
With hormones With hormones
PTH
Sag/mi
GLU ISO
SXlO'M 10'M
AVP CT
10'M 0.2 mg/mI
Basal PTH GLU ISO
activity 5 g/ml 5X10'M 10'M
AVP
l0'M
CT
0.2 mg/mI
M, 39 C 14.3
2 F, 69 C 25.4
3 F, 70 C 25.5
4 M, 63 C 7.1
5 M, 58 C 11.6
6 M, 56 C 6.5
7 M, 78 C 8.7
144.2
193.7
157.9
54.7
141.8
57.3
44.6
19.6 16.9
33.4 29.4
33.1 27.2
12.0 7.8
18.2 13.8
10.8 7.3
12.0 10.9
22.8 17.4
44.3 31.0
38.9 22.8
13.2 9.7
20.3 14.0
20.2 11.2
10.5 10.2
9.3 9.8 4.0 4.4
20.9 34.3 19.0 24.1
4.5 1.7 2.2 2.4
5.8 4.5 6.1 6.2
8.5 9.6 9.6 10.4
5.3 4.9 4.7 4.2
5.5 5.6 5.6 5.7
10.9
19.1
3.6
6.2
10.0
4.6
5.2
7.8
16.1
2.3
5.4
7.6
4.2
5.3
Mean:
SEM
8.5 10.0 7,3 8.2
±2.1 +2.8
8.5
+2.0
6.9
8 M, 42 D 25.4
9 M, 72 D 12.4
10 F, 69 D 5.5
175.9
180.5
41.7
38.1 45.8
20.3 15.2
6.8 6.3
43.2 23.5
25.5 20.4
8.5 8.6
23.5 29.7 98.3 123.6
13.7 15.3 44.9 54.0
8.8 8.7 18.3 22.8
18.0
10.8
8.7
17.4
10.3
10.3
Mean: 14.2
SEM
119.2
19.6
20.2 18.0 25.0 16.9 15.3 17.9 53.8" 66.8'
+6.2
12.5 12.6
Increase over basal
activity (%) SEM
+767
+5
+45 +22
+6
+82 +29 12 +2l8 +294! —15 — II
'Specific activity of adenylate cyclase is given in pmoles of cAMP/mm/mg of protein. Stimulation in normal cortex by all hormones was
significant (P < 0.05 or better; paired t test). In clear-cell RAC, none of the hormones produced significant stimulation. Basal activities
were not significantly different among cortex or clear-cell or dark-cell RAC. Activity of adenylate cyclase in kidneys bearing clear-cell
adenocarcinoma did not differ significantly from the kidneys bearing dark-cell adenocarcinoma, either basal or after hormonal stimulation.
b Abbreviations used are PTH, parathyroid hormone; GLU, glucagon; ISO, l-isoproterenol; AVP, vasopressin, CT, calcitonin.
C, adenocarcinoma of clear-cell type; D, adenocarcinoma of dark-cell type.
"Significantly higher than activity (basal or in presence of GLU) of cortex or clear-cell RAC (P < 0.05).
'Significantly higher than activity (basal or in presence of ISO) of cortex or clear-cell RAC (P < 0.05).
Increase significantly higher than with same hormones in normal cortex (P < 0.001).
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Table 6. Effect of prostaglandins (PGEI and PGEZ) and parathyroid hormone (PTH) on adenylate cyclase activity in 600 X g pellets
Adenylate cyclase activity, pmoles/min/mg ofprotein
With arachidonic
With PGEL With PGE2 acid With PTH With PTH, 5g/ml, +
Tissue source5 Basal 3 X l0°M 3 )< l0°M 3 >< l0-°M 5g/mf PGEZ, 3 >< lO°roi
Cortex(N 9) 7.8 + 0.6 15.6 + l.9 15.2 1.4° 7.5 1.0 71.4 10.7° 84.2 138C,d% — +82 18° +97 16° —5 + 8 +813 + 130° 971 + 159'd
Clear-cell RAC 4.8 1.1 5.7 1.0° 6.2 + 0.9°
(N=7)% — +28 + 1 f.e +46 + l7°
Values represent the mean + SEM.
N denotes the number of observations.
Significantly higher than basal activity (P < 0.05 or better; paired t test).
Significantly higher than with PTH alone (P < 0.05; paired I test).
Stimulation significantly lower than % increase in cortex (P < 0.05).
tioned tested humoral agents, besides PTH (Table 2),
only PGE2 significantly (P < 0.025) stimulated
adenylate cyclase, and this occurred only in the l0 X
g pellets (values not shown here).
Neither clear-cell nor dark-cell RAC adenylate cy-
clase was stimulated by PTH, CT, or AVP (Table 5).
Adenylate cyclase from clear-cell RAC was signifi-
cantly stimulated by both PGE1 and PGE2, but the
extent of stimulation (percent of increase over basal
activity) was markedly less than that seen in normal
cortex (Table 6). Tn two 600 X g preparations from
dark-cell RAC in which response to prostaglandins
was tested, PGE1 and PGE2 both stimulated adeny-
late cyclase, similar to that seen in clear-cell RAC
preparations (not shown here).
The two types of RAC differed markedly in the
sensitivity of adenylate cyclase to stimulation by
GLU and ISO. While clear-cell RAC adenylate cy-
clase was completely unresponsive to these two
agents, as it was to other polypeptide hormones
(PTH, AVP, and CT), adenylate cyclase preparations
from all three dark-cell RAC not only were stimu-
lated by GLU and ISO but the extent of the stimula-
tion by these two agents (in terms of the maximal
percentage of increase over the basal activity) was far
higher than that seen in normal cortex (Table 5, Fig.
1). The stimulation of dark-cell RAC adenylate cy-
clase by GLU and ISO was dose-dependent, and
concentrations of agents required for maximal in-
crease in the enzyme activity were apparently not less
than that for the enzyme from normal Cortex (Fig, 1).
Also, as in normal cortex, stimulation by ISO was
completely blocked by propranolol (d, l-propranolol,
Sigma Co.) (Table 7).
Because, in human tissue, the absent or borderline
response of adenylate cyclase to hormones (cate-
cholamines) can be unmasked by addition of
Gpp(NH)p [291 and Gpp(NH)p was shown to poten-
tiate the PTH [30] stimulation of adenylate cyclase,
we attempted to restore hormone responsiveness in
clear-cell RAC by the addition of this nucleotide
derivative. At a concentration of 104M, Gpp(NH)p
alone greatly stimulates adenylate cyclase both in
normal cortex and in tumor tissue (Tables 2 and 8).
Therefore, we tested a lower concentration (107M),
which stimulated the enzyme slightly but significantly
(Table 8). Whereas l01M Gpp(NH)p consistently
increased the activity of cortical and clear-cell RAC
adenylate cyclase, in the presence of Gpp(NH)p no
effect of PTH (used at concentrations that would
produce maximal stimulation of normal cortical
adenylate cyclase) was detected in clear-cell RAC
(Table 8).
To examine the possibility that a hormone-respon-
sive adenylate cyclase complex may sediment in clear-
cell RAC preparations with fractions other than the
600 X g pellet, the effect of PTH (Table 2), as well as
200
150
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E
ii,
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—
9
0/
—
_-.e-—-—,.—---i i
0
/-isoprotereno, st
,0'
0
d
1O_810_71O_61O51O_4
Glucagon, M
Fig. 1. Stimulation of adenylate cyclase by glucagon and by I-
isoproterenol in 600 >< g pellet of normal renal cortex and dark-cell
renal adenocarcinoma. Stimulation is expressed as percent of in-
crease (%) in enzyme activity as compared with basal activity
(without addition of hormones). The solid line denotes the normal
cortex; dashed line, dark-cell adenocarcinoma. Each point is mean
values from three different tissues.
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Table 7. Effect of propranolol (PROP) on stimulation of adenylate
cyclase by isoproterenol (ISO) in renal cortical tissue and in dark-
cell renal adenocarcinomatous tissue (RAC)
Tissue sourc&'
Adenylate cyclase activity
pmoles/min/mg ofprotein
Basal With With l0- M ISO
activity 10 M ISO + I0 M PROP
Cortex (N = 5)% 12.9 5.9 14.9 5.9 11.1 + 4.3— +24±6 —10±10
Dark cell RAC
(N =3)%
20.6 9.9 59.7 19.5 20.4 6.5
— +196±65 +6±9
a Values are the mean + SEM.
b N denotes the number of observations.
other hormones, was tested in all fractions of clear-
cell RAC. GLU, ISO, CT, and PGEZ had no stimu-
latory effect on tumor adenylate cyclase in the 10 X
g pellet, the l0 X g pellet, or the cytosol (data not
shown here).
Many hormones acting through cAMP mediation
may exert their ultimate functional effect through
activation of cAMP-dependent protein kinase [31].
Therefore, activity of this enzyme also was examined
in cytosol of normal kidney and in both types of
RAC. Protein kinase was present in cortex and in
tumor tissue and was markedly stimulated by cAMP
(Table 9). There was no significant difference in the
specific activity of protein kinase or in the extent of
its stimulation by cAMP between normal cortex and
RAC of either type (Table 9).
Discussion
Abnormal cAMP and cGMP metabolism is fre-
quently associated with accelerated (namely, neo-
plastic) cell growth and differentiation [1—3].
Whether such changes are due to pathogenetic fac-
tors has not yet been resolved [1—3]. Present results
show that alterations in properties of enzymes, which
are major determinants of cyclic 3',5'-nucleotide me-
tabolism, occur in human renal adenocarcinoma
(RAC)—a tumor composed of transformed cells
from proximal convoluted tubules [101.
Basic properties of adenylate cyclase from normal
human cortical tissue, including responsiveness to
hormonal and nonhormonal agents [15—17], and dis-
tribution of specific activities between subcellular
fractions do not differ from those observed in studies
done on renal cortex of experimental animals
[15—17]. Also, the subcellular distribution of cAMP
phosphodiesterase with predominant activity in cyto-
sol resembles findings seen in experimental animals
[15]. The specific activities of the adenylate cyclase
stimulated by Gpp(NH)p or by sodium fluoride in
RAC, with a few exceptions (Table 2), did not differ
substantially from that seen in normal cortical tissue,
indicating that the catalytic subunit and the guanyl
nucleotide binding site [3 1—33] are preserved in neo-
plastically transformed cells, unlike the finding in
some experimental animal models of tumor or tumor
cells grown in tissue culture [3].
The most stiking difference between normal cortex
and RAC is the altered response to humoral agents.
The complete absence of stimulation by parathyroid
hormone (PTH) and by calcitonin (CT) in both cell-
types of RAC tissue and also of stimulation by gluca-
gon (GLU) and /-isoproterenol (ISO) in clear-cell
RAC tissue may be due to the deletion of the recep-
tors or to an impairment in the "coupling mecha-
nism" [15, 33] in the hormone-sensitive adenylate
cyclase complex. Present results do not allow differ-
entiation between these possibilities. The former al-
ternative is similar to that found in some experimen-
tal tumors of animals [4, 34—36] or in human adrenal
tumors [4] in which loss of hormonal stimulation of
Table 8. Effect of guanylylimidodiphosphate (Gpp[NHlp) on adenylate cyclase in 600 X g pellet from renal cortical tissue and from clear-
cell renal adenocarcinomatous tissue (RAC)B
Tissue sourceb Basal activity
Adenylate cyclase activity, pmoles/rnin/mg of protein
With Gpp(NH)p
With l0- MGpp(NH)p +
5ig/ml of PTHl0- M 10 ri
Cortex (N = 6)%a
Clear cell RAC (N = 6)%e
10.9 1.5
—
5.8 1.3
—
26.2 5.2c
+145 35
23.1 4.0c
+336 68
75.3 1 l.0c
+617 79
63.1 l0.8
+1,129 276
—
19.8 3gd
+265 55d
a Values are the mean SEM.
b N denotes the number of observations.
Significantly higher than basal activity (P < 0.05; paired I test).
Not significantly (P > 0.05) different from activity with 107M Gpp(NH)p alone.
Percentage increase in activity in presence of Gpp(NH)p above basal activity was significant under all conditions (P < 0.01, paired t test).
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Values are the mean + SEM.
b N denOtes number of observations.
Activity in presence of added histones
histones.
Table 10. Specific activities of guanylate cyclase (pmoles/min/mg of protein) from rat renal cortex
Condition
600Xg
pellet
l04Xg
pellet
lO6Xg
pellet Cytosol
Basal 16.7 + 2.3 17.5 1.2 20.1 4.7 82.2 4.6
With 1 m sodium azide 96.4 7.4 78.7 6.3 92,2 12.2 493.1 + 87.0
Values are the mean + SEM of three measurements.
Table 9. Protein kinase activity in cytosol from renal cortical
tissue and from renal clear-cell and dark-cell adenocarcinomatous
tissues
Tissue
sourceb
Protein kinase activity
pmoles of '2P/min/mg ofprotein
Net histone
Without histones phosphorylation
No cAMP With 108M No cAMP With l06M
added cAMP added cAMP
Cortex (N = II) 0.8 0.1 1.2 0.1 6.1 0.7 30,2 2.6
Clear-cell RAC
(N =8)
0.8 1.2 1.2 0.1 4.4 0.4 23.3 1.7
Dark-cell RAC
(N = 3)
0.8 0.3 2.2 0.4 7.1 1.4 29.9 6,9
adenylate cyclase is associated with an absence of
hormonal binding. Unusually high dependence of
hormonal response on quanyl nucleotides [29, 30]
also does not seem to be the basis for the absent
response to PTH in RAC (Table 8).
Lack of stimulation of RAC adenylate cyclase by
vasopressin (AVP) is not unexpected, because AVP-
stimulated adenylate cyclase in normal cortex is likely
due to the presence of cortical collecting tubules and
ducts [37], and RAC is obviously derived from prox-
imal tubular cells [10], which do not contain the
AVP-sensitive adenylate cyclase system [37]. Re-
tained, although diminished, sensitivity of RAC
adenylate cyclase to prostaglandins E seems to be
analogous to the findings observed in other epithelial
human tumors [4, 5], with the exception of one case
of adrenal tumor [4]. Thus, molecular components
that are involved in prostaglandin-binding and in
stimulating the adenylate cyclase appear to be rela-
tively resistant to changes due to neoplastic transfor-
mation.
Remarkably high (apparently supernormal) stimu-
lation of adenylate cyclase by GLU and ISO in dark-
cell RAC indicates that the receptor-adenylate cy-
clase complexes for these two agents are preserved
and actually may be increased in number in this type
of RAC. Higher-than-normal stimulation of adeny-
late cyclase by hormones was reported in some ani-
mal systems [3, 38—40]. An alternative explanation
for this finding, which should be considered, is the
possibility that dark-cell RAC is composed of a sub-
population of cells that are specifically responsive to
ISO and GLU but not to PTH or CT.
Regardless of the underlying mechanism for the
different sensitivity of dark-cell RAC, as opposed to
that of clear-cell RAC, to GLU and ISO, the differ-
ence may explain the different metabolic behavior
and morphologic appearance of these two RAC
types. GLU and ISO are known, through mediation
of cAMP and activation of protein kinase, to inhibit
glycogen synthesis [37] and to stimulate glycoge-
nolysis [41] and lipolysis [42] in other tissues. Thus,
unresponsiveness of adenylate cyclase to GLU and to
ISO in clear-cell RAC may be the cause of the exces-
sive accumulation of glycogen and lipids typically
found in these cells (which causes their "clear" ap-
minus activity without
pearance), because these cells may be resistant to
glycogenolytic and lipolytic effects of glucagon and 3-
catecholamines. This is a tentative interpretation,
however, and should be guarded until more direct
proof of the proposed causal relationships is pro-
vided. It is not excluded that other factors unrelated
to cAMP-mediated mechanisms may play a role in
abnormal glycogen and lipid metabolism in RAC.
In a striking contrast to the findings on rat kidney
cortex [9, 43, 44], in human tissue the highest specific
activity of guanylate cyclase was found in particulate
fractions that sedimented at low centrifugal speeds.
To assure that this difference between normal human
cortex and rat cortex is not accounted for by the
method used, we prepared and assayed, for guanylate
cyclase, subcellular fractions from renal cortex of
normal rats (Sprague-Dawley strain) in the same way
as the fractions from human kidney cortex. The rela-
tion of guanylate cyclase activities between fractions,
with cytosol having the highest specific activity(Table 10), was almost identical to the results de-
scribed by Criss, Murad, and Kimura [9]. Our find-
ings are not entirely unexpected because unlike that
with adenylate cyclase, considerable differences were
observed in the subcellular distribution of guanylate
cyclase among different growth stages of the same
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tissue [45]. In RAC, the spectrum of guanylate cy-
clase specific activities was reversed: the highest activ-
ity was found in cytosol. It should be noted that, in
the cortex of the rabbit kidney, the specific activity of
guanylate cyclase in glomeruli was found to be about
50 times higher than that in tubules [46], and the
activity was primarily (about 85%) bound on par-
ticles, whereas in tubules, guanylate cyclase of a much
lower specific activity was found mostly (about 80%)
in cytosol [46]. If the same relationships hold true for
human kidney, the finding of lower particle-bound
guanylate cyclase activity in RAC may be partly due
to the absence of glomeruli in tumor tissue. Glome-
ruli, which constitute only about 8% of renal cortex
[47], are rich in guanylate cyclase activity [46]. Be-
cause there would be little difference between the
relative content of tubular cells in tumor and cortex
tissue, the high specific activity of the cytosolic
guanylate cyclase in RAC (of both cell types) prob-
ably reflects an increase in the total guanylate cyclase
activity of the tumor tissue. The shift toward higher
soluble and lesser particle-bound guanylate cyclase
specific activity in RAC (Table 4) resembles changes
described in the guanylate cyclase in rat kidneys that
have undergone growth of compensatory renal hy-
pertrophy [8]. Present findings in the properties of
human RAC guanylate cyclase, however, differ
markedly from observations in transplantable kidney
tumors [9] in rats, in which the specific activity of
guanylate cyclase was lower in all fractions than in
normal rat renal cortex, the highest specific activities
were in cytosol of both normal cortex and tumors,
and the tumor enzyme was not stimulated by sodium
azide [9].
Cyclic 3',5'-nucleotide diesterase activities were
measured using either cAMP or cGMP as substrate.
With each of these substrates, the highest activity was
found in the cytosol of both normal cortex and of
RAC. Cyclic GMP phosphodiesterase activity was
markedly lower in clear-cell RAC cytosol and l0 X g
pellet than in cortex. This difference appears to be
specific, because no significant differences were noted
between RAC and cortex in other enzyme com-
ponents of cytosol, such as cAMP phosphodiesterase
activity and protein kinase activity, and because
LDH activity was even higher in clear-cell RAC than
in cortex (Table 3). Cyclic AMP diesterase activities,
and to a lesser degree cGMP diesterase activities,
were markedly higher in dark-cell RAC preparation,
namely cytosol. The striking increase in cAMP phos-
phodiesterase activity in dark-cell RAC is puzzling. It
was, however, shown that in cultured cells, cAMP
phosphodiesterase can be induced by either the addi-
tion of dibutyryl cAMP or the endogenous accumula-
tion of cAMP in response to ISO [48]. Since dark-cell
RAC contains adenylate cyclase that is highly sensi-
tive to ISO and is not deficient in protein kinase,
which is required for such induction [48], high cAMP
phosphodiesterase in these cells may be secondarily
induced by a high rate of endogenous cAMP syn-
thesis. Many tissues, including those of the kidney
[15], usually contain several different relative sub-
strate specificities to these two nucleotides [49]. The
present results cannot determine whether increased
hydrolysis of cGMP in dark-cell RAC is due to
higher activity of cAMP phosphodiesterase, with
cross-specificity for cAMP and cGMP, or is due to
the simulataneous induction of two enzymes that are
directed specifically against cAMP and cGMP, re-
spectively.
Several tentative conclusions can be considered
from the present results. Increased soluble—by impli-
cation of tubular origin [46]—gyanylate cyclase activ-
ity in conjunction with decreased cytosolic cGMP
phosphodiesterase activity in clear-cell RAC may fa-
vor high levels of cGMP in this tissue. Although the
basal specific activities of adenylate cyclase and
cAMP phosphodiesterase were not different between
RAC and normal cortex, complete unresponsiveness
to most of the natural hormonal stimulants (such as
PTH, CT) may cause, in situ, the rate of cAMP
formation to be always lower in tumorous tissue than
in normal cortex, where adenylate cyclase is always
subjected to hormonal stimulation. In dark-cell
RAC, the increased synthesis of GLU and f3-cate-
cholamine-dependent cAMP may conceivably be off-
set by the high activity of cAMP phosphodiesterase.
Thus, as a common feature, the alterations in en-
zymes of cyclic 3',5'-nucleotide metabolism in RAC
may be expected to favor higher tissue accumulation
of cGMP and lower accumulation of cAMP. Such
reciprocal changes in cAMP and cGMP tissue levels
were found in kidneys undergoing renal hyperplasia
or postneonatal growth [8], as well as in many other
studies, and are believed to be associated with accel-
erated cell growth, including neoplastic growth [1—3].
Differential changes in hormonal regulation of
cAMP synthesis might be the underlying cause of
anomalies in intermediary (glycogen and lipid) me-
tabolism of RAC.
Our results also show that properties of enzymes of
cyclic 3',5'-nucleotide metabolism of the normal hu-
man kidney and of spontaneously occurring renal
tumors may differ substantially from those of experi-
mental renal tumors [9] or from properties observed
in transformed cells from some other organs grown in
tissue cultures [1—3]. Direct studies on the elements of
cyclic nucleotide metabolism in human kidney, al-
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though limited by the availability or the homogeneity
(or both) of the obtained tissue preparations, are
critically important (in conjunction with studies on
animal models) for the elucidation of the role of
cyclic 3',5'-nucleotides in the pathogenesis and the
metabolic properties of renal neoplasia.
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